Drug Smackdown: Amgen vs. Eli Lilly DailyFinance Interleukin-17 inhibitors from Amgen (NAS: AMGN) and Eli Lilly (NYS: LLY) were both tested in patients with moderate to wicked plaque psoriasis . Here's a table looking At the efficacy data for the most effective medication for each drug. Eli Lilly Phase II disease of the skin study meets primary termination Pharmaceutical Business Review each 4 news articles » Link To Article
No comments:
Post a Comment